



Medinice S.A.
Ul. Stefana Hankiewicza 2
02-103 Warsaw

30 MARCH 2026

**CURRENT REPORT NO. 9/2026
DATED 30 MARCH 2026**

Title: Admission and introduction to stock exchange trading of series N, L2, L3 shares

Legal basis: Article 56 section 1 item 2 of the Act on Public Offering – current and periodic information

The Management Board of Medinice S.A. with its registered office in Warsaw ("Company") informs that the Management Board of the Warsaw Stock Exchange S.A. adopted Resolution No. 479/2026 regarding the admission and introduction to stock exchange trading on the WSE Main Market of the Company's ordinary bearer shares of series N, L2 and L3. The following were admitted to stock exchange trading on the main market: 1,304,348 ordinary bearer shares of series N of the Company with a nominal value of PLN 0.10 each, 110,000 ordinary bearer shares of series L2 of the Company with a nominal value of PLN 0.10 each, and 176,643 ordinary bearer shares of series L3 of the Company with a nominal value of PLN 0.10 each.

The Management Board of the Warsaw Stock Exchange S.A. decided to introduce, as of 7 April 2026, the above-mentioned series N, L2 and L3 shares of the Company to stock exchange trading on the main market, provided that the National Depository for Securities S.A. performs, on 7 April 2026, their assimilation with the Company's listed shares designated with the code "PLMDNCE00016".

*Patient friendly smart routing
therapies for quality of life*

Medinice S.A.
biuro@medinice.pl
www.medinice.pl